Delving into the Latest Updates on Haakon Ragde Foundation with Synapse

Overview

Author: Reisæter, Lars Anders ; Halvorsen, Ole Johan ; Førde, Kristina ; Biermann, Martin ; Azeem, Waqas ; Gjertsen, Bjørn T. ; Riethdorf, Sabine ; Melve, Guro Kristin ; Kristoffersen, Einar Kleboe ; Kalland, Karl-Henning ; Thomsen, Liv Cecilie Vestrheim ; Almås, Bjarte ; Bahn, Duke ; Helle, Svein Inge ; Pantel, Klaus ; Ragde, Haakon ; Beisland, Christian ; Honoré, Alfred ; Øyan, Anne Margrete ; Akslen, Lars

3029 Background: Dendritic cell (DC)-based cryoimmunotherapy (CryoIT) was used to treat metastatic castration-resistant prostate cancer in a Phase I clinical trial. Primary objective was safety of treatment. Secondarily, clinical, radiological and immunological treatment responses were investigated. Methods: In 18 patients cryoablation by a freeze-thaw process under general anesthesia was performed, followed by intratumoral autologous immature DC injection. In the last 9 patients checkpoint inhibition of either CTLA-4 or PD-1 was added. Subjects had minimum 46 weeks follow-up. Adverse events (AEs) and blood analyses were registered at all visits. Disease progression was determined by three imaging modalities according to (i)RECISTv1.1 and progression-free survival (PFS) by Kaplan-Meier method. Circulating tumor cells (CTC/7.5 mL, CellSearch) and ultradeep T-cell receptor (TCR) b-chain sequences (TCRSafe) were enumerated. Patients were separated by CTC into none (n=10), 1-4 (n=4) and ≥ 5 (n=4). Health related quality of life (HRQoL) measured by EORTC-QLQ C30 questionnaire were answered at inclusion, and 10, 22 and 46 weeks post CryoIT. Scores were calculated according to the EORTC manual. Results: Subjects progressing within 22 weeks had higher PSA (p=0.03). AE profile of the total cohort (n=18) was comparable with interim reports (n=13); of 20 possible DC-related AEs one was severe (urinary retention) and 19 mild-to-moderate, and spread independent of treatment regime. Maximum tolerated dose of DC was not reached. By 46 weeks, imaging showed 6 patients partial response or stable disease. Median PFS was 150 days in total cohort. Pretreatment CTC counts ≥5 indicated higher progression rates and recurring CTC. Ultradeep TCR-sequencing showed more prevalent and higher expressed (>5-fold) new TCR clonotypes at 2-6 weeks in men without progression. Participants reported high and stable HRQoL scores throughout the study. However, presence of CTC was associated with worse HRQoL scores at week 10 (p=0.031) and 22 (p=0.005). Conclusions: DC treatment seems safe and well tolerated, also combined with checkpoint inhibitors. Effect is indicated in subjects with moderate pre-treatment PSA levels. Immune responses are suggested by higher number of novel TCR clonotypes in men with non-progressive disease. Clinical trial information: NCT02423928 .

20 May 2018·Journal of Clinical Oncology

Dendritic cell (DC) based cryoimmunotherapy (CryoIT) in a prospective phase I trial of metastatic castration resistant prostate cancer (mCRPC): Interim analysis.

Author: Kalland, Karl-Henning ; Gjertsen, Bjorn T. ; Ragde, Haakon ; Haslerud, Torjan ; Frugård, Jannicke ; Kristoffersen, Einar Kleboe ; Honoré, Alfred ; Reisæter, Lars Anders ; Bahn, Duke ; Almås, Bjarte ; Melve, Guro Kristin ; Beisland, Christian ; Halvorsen, Ole Johan ; Helle, Svein Inge ; Biermann, Martin ; Oyan, Anne Margrete ; Kvalheim, Gunnar ; Thomsen, Liv Cecilie Vestrheim ; Pantel, Klaus ; Rørvik, Jarle Tor

e17014Background: Interim analysis data are presented for 13 pts with mCRPC treated with DC based CryoIT and at least 3 months follow-up (FU). CryoIT exposes tumor antigens in cryoablated tissue to...

100 Deals associated with Haakon Ragde Foundation

Login to view more data

100 Translational Medicine associated with Haakon Ragde Foundation

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data